HOME / Notice / News / EN
- 9th Research Conference held at Kosin University Gospel Hospital in Busan; discussion on adopting ‘multi-omics’ for mechanism elucidation. Continued efforts to review globally advanced technologies for data-driven efficacy validation - NKCL Bio Group proposes integrated immune monitoring system; ...
Kosin University Gospel Hospital (Hospital Director Choi Jong-soon) and NKCL Bio Group (Chairman Shin Dong-hwa) are set to strengthen competitiveness in the field of advanced regenerative medicine through NK cell-based next-generation immune cell therapy research and clinical cooperation. Kosin Unive...
MOU Signing Ceremony Held at Kosin University Gospel Hospital on February 9 (Mon) Joint Advancement in Clinical Research for NK Cell Combination Therapy Targeting Hepatocellular Carcinoma "We Will Accelerate the Realization of Precision Medicine Based on Advanced Regenerative Medical Data" Kosin Univ...
Anticipates Securing Leading Position in Early Diagnosis and Preventive Healthcare Market for Cancer, Dementia, and Other Intractable Diseases Global health tech company Molecular You (MYCo) and NK cell therapy research biotech NKCL Bio Group Co., Ltd. (NKCL) signed a Memorandum of Understanding (MOU...
Spurring Growth as a Domestic Biotech Company Entering the Global Market with NK Cell Automated Incubators NKCL Bio Group (hereinafter referred to as NKCL) announced that it has successfully developed a multi-person (currently up to 16-person) NK cell automated incubator ‘RK-NKTM ACS-II (hereinafter...